Diploma in Dermatology

Introduction:
Vitiligo is a chronic skin condition characterized by the development of white patches on the skin due to the loss of melanocytes, the cells responsible for producing skin pigment (melanin). These depigmented patches can appear on various parts of the body, including the face, hands, feet, and around body openings like the eyes and mouth. Although vitiligo can affect people of all skin types, it may be more noticeable in individuals with darker skin. The condition is not life-threatening or contagious but can significantly impact a patient's psychological and emotional well-being.

Etiology:
The exact cause of vitiligo is not fully understood, but it is believed to result from a combination of genetic, autoimmune, and environmental factors:

• Autoimmune Hypothesis: The most widely accepted theory suggests that vitiligo is an autoimmune disorder in which the body’s immune system mistakenly attacks and destroys melanocytes.

• Genetic Factors: There is a hereditary component to vitiligo, with a higher likelihood of occurrence in individuals with a family history of the condition or other autoimmune disorders.

• Environmental Triggers: Certain factors, such as sunburn, emotional stress, chemical exposure, or physical trauma to the skin (Koebner phenomenon), can trigger or exacerbate vitiligo in predisposed individuals.

• Neurogenic Hypothesis: Some theories propose a neurogenic factor where the nervous system releases substances that may be toxic to melanocytes.

• Oxidative Stress: Elevated levels of reactive oxygen species and antioxidant imbalance in the skin may contribute to melanocyte destruction.

Differential Diagnosis:
When diagnosing vitiligo, it is essential to distinguish it from other conditions that cause hypopigmentation or depigmentation of the skin. Differential diagnoses include:

• Pityriasis Versicolor: A fungal infection that causes scaly, hypopigmented patches, typically on the trunk. Unlike vitiligo, these patches are not completely depigmented and can show scaling.

• Tinea Versicolor: A yeast infection causing patches that may be lighter or darker than the surrounding skin, usually accompanied by mild scaling.

• Post-inflammatory Hypopigmentation: This occurs following an inflammatory skin condition like eczema or psoriasis, where the affected areas become lighter but not fully depigmented.

• Piebaldism: A rare genetic disorder characterized by congenital depigmented patches, typically on the forehead, chest, and abdomen, associated with a white forelock of hair.

• Lichen Sclerosus: A chronic condition causing white, shiny patches that are often itchy and affect the genital and anal areas.

• Albinism: A genetic condition involving the complete or partial absence of melanin production, affecting the skin, hair, and eyes from birth.

• Leprosy: Chronic infection caused by Mycobacterium leprae can lead to hypopigmented patches with sensory loss, particularly in endemic areas.

Vitiligo: Treatment

The primary goals of vitiligo treatment are to restore the skin's color (repigmentation) and improve the patient's cosmetic appearance and quality of life. Treatment options vary based on the extent, location, and progression of the disease, as well as the patient’s age and preference. Although there is no cure for vitiligo, various therapies can help manage the condition and achieve significant repigmentation in affected areas.

1. Topical Treatments:

• Corticosteroids: Topical corticosteroids are commonly used as first-line treatment for localized vitiligo. They work by reducing inflammation and the immune response that targets melanocytes. Mild to moderate corticosteroids are generally used, and treatment duration is carefully monitored to avoid skin thinning and other side effects.

• Calcineurin Inhibitors: Topical calcineurin inhibitors, such as tacrolimus and pimecrolimus, are effective, especially for facial and intertriginous areas. They are often preferred over corticosteroids for long-term use due to a lower risk of side effects.

• Vitamin D Analogues: Calcipotriol, a vitamin D analogue, may be used alone or in combination with corticosteroids to promote repigmentation.

2. Phototherapy:

• Narrowband UVB (NB-UVB): This is the most widely used and effective phototherapy for vitiligo. NB-UVB treatment involves exposure to ultraviolet light two to three times per week, stimulating melanocyte migration and proliferation in the affected areas.

• Excimer Laser: This laser delivers targeted UVB light to small areas of vitiligo, making it suitable for localized patches, especially on the face and neck.

• PUVA Therapy: Involves the use of psoralen (a photosensitizing agent) combined with UVA light exposure. While effective, it has a higher risk of side effects, such as increased skin cancer risk and phototoxicity, compared to NB-UVB.

3. Systemic Treatments:

• Oral Corticosteroids: Short courses of oral corticosteroids may be used to control rapidly spreading vitiligo, often as a bridge to other treatments like phototherapy.

• Immunomodulators: Systemic immunosuppressive drugs (e.g., methotrexate, cyclosporine) are occasionally used in severe, widespread vitiligo, although they are not commonly first-line treatments.

4. Surgical Treatments:

• Skin Grafting: In cases of stable vitiligo, surgical options such as autologous skin grafts or melanocyte transplants can be considered. Techniques include punch grafting, suction blister grafting, and melanocyte-keratinocyte transplantation.

• Micropigmentation (Tattooing): This technique involves implanting pigment into the skin, which can be useful for small areas, particularly on the lips.

5. Depigmentation:

• For patients with widespread vitiligo covering more than 50% of the body, depigmentation of the remaining pigmented skin may be an option. Monobenzone or hydroquinone is used to achieve uniform skin color by removing the remaining pigment. This is a permanent and irreversible treatment.

6. Psychological Support:

• Vitiligo can significantly impact a patient's psychological well-being. Counseling, support groups, and psychotherapy may be beneficial in helping patients cope with the emotional and social challenges of the condition.

7. Cosmetic Camouflage:

• Makeup and Self-Tanners: These can be used to cover depigmented areas temporarily. Products are available that are waterproof and long-lasting.

• Dyes and Stains: Special dyes can also provide temporary coverage and improve the appearance of affected areas.

8. New and Emerging Treatments:

• Janus Kinase (JAK) Inhibitors: Topical and systemic JAK inhibitors, such as tofacitinib and ruxolitinib, are emerging as promising treatments for vitiligo by inhibiting pathways involved in the autoimmune response against melanocytes.

Introduction:

Psoriasis is a chronic, immune-mediated skin disorder characterized by the presence of well-demarcated, erythematous plaques with silvery scales. These lesions commonly affect the scalp, elbows, knees, and lower back but can occur anywhere on the body. Psoriasis is associated with systemic involvement, including psoriatic arthritis and increased cardiovascular risk.

Etiology and Pathogenesis:

• Genetic Factors: Psoriasis has a strong genetic component, with a higher prevalence in individuals with a family history of the condition. Several genetic loci, including PSORS1 on chromosome 6, are implicated.

• Immune System Dysfunction: Psoriasis is driven by an overactive immune response, involving T-cells and other immune mediators that stimulate keratinocyte proliferation and inflammation.

• Environmental Triggers: Factors such as infections (particularly streptococcal throat infections), stress, skin trauma (Koebner phenomenon), and certain medications (e.g., beta-blockers, lithium) can trigger or exacerbate psoriasis.

Clinical Features of Psoriatic Lesions:

• Plaque Psoriasis: The most common form, characterized by raised, inflamed, red lesions covered with a silvery-white scale. Plaques are typically symmetrical and may be itchy or painful.

• Guttate Psoriasis: Appears as small, dot-like lesions, often triggered by a streptococcal infection, commonly seen in children and young adults.

• Inverse Psoriasis: Occurs in skin folds (e.g., underarms, groin, under the breasts) and presents as smooth, red lesions without the typical scaling due to the moist environment.

• Pustular Psoriasis: Characterized by white pustules surrounded by red skin. It can be localized (e.g., on the palms and soles) or generalized, which can be a serious condition requiring immediate medical attention.

• Erythrodermic Psoriasis: A severe, inflammatory form of psoriasis that leads to widespread redness and shedding of the skin, often accompanied by systemic symptoms such as fever and chills.

Differential Diagnosis:

• Seborrheic Dermatitis: Characterized by greasy scales and erythema, typically affecting the scalp, face, and chest, which may resemble psoriasis but has a different distribution and scale type.

• Lichen Planus: Presents with purple, polygonal, flat-topped papules, often with fine white lines on the surface (Wickham striae), primarily affecting the wrists, ankles, and mucous membranes.

• Tinea Infections: Fungal infections that can mimic psoriasis, especially in areas like the scalp or body folds. A potassium hydroxide (KOH) test or fungal culture can help differentiate these conditions.

• Pityriasis Rosea: Typically presents as a "herald patch" followed by a widespread rash in a "Christmas tree" pattern on the back. The lesions are oval and have a fine scale, unlike the thick plaques of psoriasis.

• Eczema: Features red, itchy, scaly patches that can sometimes be confused with psoriasis. Eczema often affects flexural surfaces and is usually more pruritic.

Treatment:

• Topical Treatments: First-line therapies include corticosteroids, vitamin D analogues (e.g., calcipotriol), and topical retinoids. For scalp psoriasis, medicated shampoos containing tar or salicylic acid are used.

• Phototherapy: UVB light therapy is effective for moderate to severe psoriasis. Phototherapy helps slow down skin cell turnover and reduce inflammation.

• Systemic Treatments: For extensive or refractory psoriasis, systemic treatments include methotrexate, cyclosporine, acitretin, and biologic agents (e.g., TNF inhibitors, IL-12/23 inhibitors).

• Biologic Therapies: Target specific parts of the immune system, such as TNF-alpha, IL-17, or IL-23. They are used in moderate to severe cases and have shown high efficacy in reducing lesions and improving quality of life.

• Lifestyle Modifications: Stress management, smoking cessation, weight control, and avoiding alcohol can help manage symptoms and reduce flare-ups.

Complications:

• Psoriatic Arthritis: A form of inflammatory arthritis affecting some individuals with psoriasis, characterized by joint pain, stiffness, and swelling.

• Increased Cardiovascular Risk: Psoriasis is associated with an elevated risk of cardiovascular diseases, metabolic syndrome, and type 2 diabetes.

• Psychosocial Impact: Due to the visible nature of psoriatic lesions, patients may experience significant psychological distress, impacting their quality of life and self-esteem.

Introduction:

Lichen planus is a chronic inflammatory condition that affects the skin, mucous membranes, nails, and hair. It is characterized by pruritic, purple, polygonal, flat-topped papules and plaques. Although the exact cause is unknown, lichen planus is considered to be an autoimmune disorder, where the immune system attacks the skin and mucous membranes. It is most commonly seen in middle-aged adults and affects both genders equally.

Etiology and Pathogenesis:

• Autoimmune Mechanism: Lichen planus is believed to be an autoimmune disorder involving T-cell-mediated attack on basal keratinocytes, leading to inflammation and cell damage.

• Genetic Predisposition: A family history of lichen planus or other autoimmune diseases may increase susceptibility.

• Infectious Triggers: Hepatitis C virus (HCV) infection has been associated with lichen planus, particularly the oral form.

• Medications: Certain drugs, such as NSAIDs, antihypertensives, antimalarials, and gold salts, can induce a lichen planus-like reaction, known as drug-induced lichen planus.

• Environmental Factors: Stress, allergens, and contact with certain chemicals may act as triggers in susceptible individuals.

  
  

Clinical Features:

• Skin Lesions: The classic presentation includes pruritic, purple (violaceous), polygonal, flat-topped papules. These lesions commonly appear on the flexor surfaces of the wrists, forearms, ankles, and lower back. The papules may have fine white lines on their surface, known as Wickham striae.

• Oral Lichen Planus: Appears as white, lacy patches (reticular form) or as erosive, painful ulcers in the mouth. It is one of the most common forms and can significantly impact oral health.

• Nail Involvement: Nail lichen planus can lead to longitudinal ridging, splitting, thinning, or complete loss of the nail (anonychia).

• Scalp (Lichen Planopilaris): Affects hair follicles, leading to scarring hair loss (cicatricial alopecia) and is often accompanied by scalp redness and scaling.

• Genital Lesions: In men, it can affect the glans penis and present as white streaks or erosions. In women, it can affect the vulva, leading to painful erosions.

  
  

Differential Diagnosis:

• Psoriasis: Characterized by well-demarcated, erythematous plaques with silvery scales, typically on extensor surfaces.

• Lupus Erythematosus: Presents with red, scaly patches that may resemble lichen planus but often have a different distribution and associated systemic features.

• Eczema: Features itchy, red, scaly patches but usually involves flexural surfaces and lacks the violaceous color and polygonal shape of lichen planus.

• Pityriasis Rosea: Begins with a herald patch followed by a generalized rash in a Christmas tree pattern on the trunk, which is more transient and less pruritic.

• Drug Eruptions: Drug-induced lichen planus-like eruptions may resemble idiopathic lichen planus and require a careful medication history for differentiation.

  
  

Treatment:

• Topical Corticosteroids: First-line treatment for skin and oral lichen planus. They help reduce inflammation and relieve itching.

• Topical Calcineurin Inhibitors: Tacrolimus and pimecrolimus can be used, especially for oral and genital lesions, as alternatives to corticosteroids to minimize side effects.

• Systemic Corticosteroids: Used for severe or widespread lichen planus, particularly when mucous membranes, nails, or scalp are involved.

• Phototherapy: Narrowband UVB or PUVA therapy can be effective for widespread cutaneous lichen planus.

• Systemic Immunosuppressants: Medications like methotrexate, cyclosporine, and azathioprine may be used in refractory cases or when other treatments are ineffective.

• Retinoids: Oral retinoids such as acitretin can be considered, particularly for lichen planopilaris and other forms resistant to standard therapies.

  
  

Complications:

• Scarring: Especially in cases involving the scalp (lichen planopilaris) and nails.

• Mucosal Involvement: Oral lichen planus can lead to chronic pain, difficulty eating, and an increased risk of oral cancer.

• Psychological Impact: Chronic itch, pain, and visible lesions can affect quality of life, leading to anxiety or depression.

Introduction:

Scabies is a highly contagious skin infestation caused by the microscopic mite Sarcoptes scabiei var. hominis. The mite burrows into the skin, causing intense itching and a characteristic rash. Scabies affects individuals of all ages and socioeconomic backgrounds and is transmitted primarily through direct, prolonged skin-to-skin contact. Outbreaks are common in crowded environments, such as nursing homes, schools, and prisons.

Etiology and Pathogenesis:

• Causative Agent: Scabies is caused by the mite Sarcoptes scabiei var. hominis, which is an obligate human parasite. The female mite burrows into the superficial layers of the skin, laying eggs that hatch into larvae, which then mature into adult mites.

• Transmission: The primary mode of transmission is direct skin-to-skin contact, although transmission can also occur through infested clothing, bedding, or towels. It is less commonly spread through brief casual contact.

• Host Response: The itching and rash associated with scabies are primarily due to a delayed-type hypersensitivity reaction to the mite, its eggs, and fecal material. This immune response usually develops 4-6 weeks after initial infestation in individuals without prior exposure.

  
  

Clinical Features:

• Symptoms: The hallmark symptom of scabies is intense itching, which is often worse at night. This itching is due to the body’s allergic reaction to the mites.

• Skin Lesions: Typical skin findings include small erythematous papules, vesicles, and linear burrows. Burrows are most commonly seen in the web spaces of the fingers, wrists, elbows, armpits, waistline, buttocks, and genital area.

• Distribution: The lesions are usually distributed symmetrically on the body. Infants and young children may have more widespread involvement, including the palms, soles, face, and scalp.

• Crusted (Norwegian) Scabies: A severe form of scabies characterized by thick, crusted lesions containing large numbers of mites. It occurs in immunocompromised individuals, the elderly, and those with neurologic conditions, and it is highly contagious.

  
  

Differential Diagnosis:

• Eczema: Characterized by itchy, red, inflamed skin, but typically lacks the burrows and specific distribution pattern of scabies.

• Contact Dermatitis: Involves itching and a rash in response to skin contact with allergens or irritants, often localized to the contact area.

• Impetigo: A bacterial skin infection with honey-colored crusts, often caused by Staphylococcus aureus or Streptococcus pyogenes, not associated with burrowing mites.

• Bedbug Bites: Typically present as clusters of itchy bites on exposed skin areas, often with a linear pattern, but without the presence of burrows.

• Folliculitis: Infection of hair follicles presenting as red, inflamed pustules, typically without the characteristic burrows of scabies.

  
  

Diagnosis:

• Clinical Examination: Diagnosis is primarily clinical, based on the characteristic symptoms, lesion distribution, and presence of burrows.

• Microscopic Examination: Confirmation can be obtained by scraping lesions and examining the material under a microscope to identify mites, eggs, or fecal matter.

• Dermatoscopy: A handheld dermatoscope may be used to visualize burrows and mites in the skin.

Treatment:

• Topical Scabicides:

  • Permethrin 5% Cream: The first-line treatment for scabies. It is applied from the neck down (or from head to toe in infants and the elderly) and washed off after 8-14 hours.

  • Benzyl Benzoate: Used in some regions, effective but may cause irritation.

  • Sulfur Ointment: Safe for use in infants and pregnant women, although less cosmetically acceptable due to its odor and texture.

• Oral Treatment:

  • Ivermectin: An oral antiparasitic drug, especially useful in cases of crusted scabies or when topical treatment fails. It is typically given as a single dose, with a repeat dose after 1-2 weeks.

• Environmental Control: All household members and close contacts should be treated simultaneously to prevent reinfestation. Bedding, clothing, and towels used by the infested person should be washed in hot water and dried in a hot dryer. Items that cannot be washed should be sealed in a plastic bag for at least 72 hours to kill the mites.

Complications:

• Secondary Bacterial Infection: Scratching can lead to bacterial superinfection, most commonly with Staphylococcus aureus or Streptococcus pyogenes, potentially resulting in impetigo or cellulitis.

• Post-Scabetic Itch: Itching may persist for several weeks after successful treatment due to ongoing allergic reactions to mite antigens.

Introduction:

Dermatophytes are a group of filamentous fungi that infect keratinized tissues, including the skin, hair, and nails, leading to infections commonly known as dermatophytoses or tinea infections. These fungi thrive in warm, moist environments and can affect individuals of all ages. Dermatophytoses are characterized by their ability to invade and digest keratin, making them unique among fungal pathogens.

Etiology and Pathogens:

• Common Genera: The main genera of dermatophytes include Trichophyton, Microsporum, and Epidermophyton. These fungi are classified based on their primary site of infection:

  • Anthropophilic: Prefer human hosts (e.g., Trichophyton rubrum, Trichophyton tonsurans).

  • Zoophilic: Prefer animal hosts but can infect humans (e.g., Microsporum canis).

  • Geophilic: Reside in soil and occasionally infect humans and animals (e.g., Microsporum gypseum).

Pathogenesis:

• Invasion of Keratinized Tissues: Dermatophytes produce enzymes like keratinases, lipases, and proteases, which allow them to invade and break down keratin in the stratum corneum, hair shafts, and nails.

• Immune Response: The host's immune system responds to the infection, leading to inflammation, which contributes to the clinical manifestations of redness, scaling, and itching.

Clinical Features:

• Tinea Capitis: Fungal infection of the scalp, characterized by scaly patches, hair loss, and sometimes inflammation or pustules (kerion).

• Tinea Corporis (Ringworm): Infection of the body, presenting as circular, erythematous, scaly plaques with a raised border, often with central clearing.

• Tinea Cruris (Jock Itch): Affects the groin area, with symptoms including red, itchy patches that may extend to the inner thighs.

• Tinea Pedis (Athlete’s Foot): Infection of the feet, commonly between the toes, presenting as itching, scaling, and sometimes blistering.

• Tinea Unguium (Onychomycosis): Infection of the nails, leading to thickened, discolored, and brittle nails.

• Tinea Barbae: Affects the beard area, presenting with inflamed pustules and scales, often contracted from animals.

Differential Diagnosis:

• Eczema: Can mimic tinea corporis but typically lacks the distinct raised borders and central clearing.

• Psoriasis: Features well-demarcated plaques with silvery scales, usually without the circular pattern seen in tinea.

• Seborrheic Dermatitis: Involves scalp and face with greasy scales, often confused with tinea capitis but has a different distribution and appearance.

Diagnosis:

• Clinical Examination: Based on characteristic lesion appearance.

• Microscopy and Culture: Skin scrapings, nail clippings, or hair samples can be examined under a microscope after potassium hydroxide (KOH) preparation to identify fungal hyphae. Fungal cultures help identify the specific dermatophyte species.

• Wood’s Lamp Examination: Some species, like Microsporum canis, fluoresce under a Wood's lamp.

Treatment:

• Topical Antifungals: First-line treatment for localized infections such as tinea corporis, cruris, and pedis includes topical agents like clotrimazole, terbinafine, miconazole, and ketoconazole.

• Systemic Antifungals: Required for extensive skin involvement, hair, nail infections, or when topical treatment fails. Common systemic agents include oral terbinafine, itraconazole, and fluconazole.

• Hygiene and Environmental Control: Regular cleaning of the affected area, keeping it dry, and avoiding sharing personal items such as towels, clothes, or hairbrushes can help prevent transmission.

  
  

Complications:

• Chronic Infection: Untreated or inadequately treated dermatophytoses can become chronic and spread to other body parts.

• Secondary Bacterial Infection: Scratching can lead to breaks in the skin, allowing secondary bacterial infections.

• Scarring and Nail Dystrophy: Prolonged infection, especially of the nails, can lead to permanent changes in nail structure.

  
  

Prevention:

• Personal Hygiene: Regular washing and thorough drying of the skin, especially in susceptible areas like the feet and groin.

• Avoidance of Shared Items: Not sharing personal items that come into contact with skin or nails.

• Protective Measures in Public Areas: Wearing flip-flops in communal showers or pool areas to reduce the risk of infection.

Antifungal Agents for Skin Infections

Antifungal agents are medications used to treat fungal infections of the skin, hair, and nails caused by dermatophytes, yeasts, and other fungi. These agents work by targeting various components of the fungal cell, disrupting its structure and function, ultimately leading to the death of the fungus. Antifungal treatments can be topical or systemic, depending on the severity and extent of the infection.

Types of Antifungal Agents:

1. Topical Antifungal Agents:

Topical antifungals are the first line of treatment for localized skin infections. They are applied directly to the affected area and are available in various forms, such as creams, ointments, gels, and sprays.

• Azoles: These inhibit ergosterol synthesis, a crucial component of the fungal cell membrane, leading to increased cell permeability and cell death.

  • Examples: Clotrimazole, Miconazole, Ketoconazole, Econazole.

  • Indications: Effective against dermatophytes, yeasts (e.g., Candida species), and molds.

  • Usage: Applied twice daily for 2-4 weeks, depending on the severity of the infection.

• Allylamines: These inhibit squalene epoxidase, an enzyme involved in ergosterol synthesis, leading to a toxic accumulation of squalene and fungal cell death.

  • Examples: Terbinafine, Naftifine.

  • Indications: Highly effective against dermatophytes and suitable for conditions like tinea pedis, tinea corporis, and tinea cruris.

  • Usage: Usually applied once or twice daily for 1-2 weeks.

• Polyene Antifungals: Bind to ergosterol in fungal cell membranes, creating pores that disrupt membrane integrity and lead to cell death.

  • Examples: Nystatin, Amphotericin B (topical).

  • Indications: Primarily used for cutaneous and mucocutaneous candidiasis.

  • Usage: Applied 2-4 times daily for 1-2 weeks.

• Others:

  • Ciclopirox: Inhibits transport of essential elements in the fungal cell, disrupting cell membrane and wall synthesis. It is used for dermatophyte infections, candidiasis, and seborrheic dermatitis.

  • Tolnaftate: Effective against dermatophytes and used for conditions like athlete’s foot and ringworm.

2. Systemic Antifungal Agents:

Systemic antifungals are used for extensive skin involvement, nail infections, or when topical treatments are inadequate. They are taken orally or intravenously.

• Azoles:

  • Examples: Fluconazole, Itraconazole.

  • Indications: Used for extensive dermatophytoses, onychomycosis (nail infections), and chronic or recalcitrant cases.

  • Usage: Typically administered once daily; the duration depends on the infection type and response to treatment.

• Allylamines:

  • Examples: Terbinafine.

  • Indications: Commonly used for onychomycosis and extensive tinea infections.

  • Usage: Terbinafine is usually taken once daily for 2-4 weeks for skin infections and longer for nail infections (6-12 weeks).

• Griseofulvin:

  • Mechanism: Disrupts fungal cell mitosis by binding to microtubules.

  • Indications: Used primarily for tinea capitis and extensive dermatophyte infections.

  • Usage: Taken orally for 4-8 weeks or longer, depending on the site and severity of infection.

• Echinocandins:

  • Examples: Caspofungin, Micafungin.

  • Indications: Primarily used for severe systemic fungal infections and candidiasis, but not typically for superficial skin infections.

Usage and Administration:

• Proper Application: For topical antifungals, it is essential to apply the medication to the affected area and surrounding skin to ensure complete coverage and efficacy.

• Compliance: Patients should be advised to complete the full course of treatment, even if symptoms improve early, to prevent recurrence.

• Hygiene: Maintaining good hygiene and keeping the affected area clean and dry can enhance treatment effectiveness and reduce reinfection risk.

Side Effects:

• Topical Antifungals: Generally well tolerated; potential side effects include mild burning, itching, or redness at the application site.

• Systemic Antifungals: Can cause gastrointestinal disturbances, liver enzyme elevation, and, in rare cases, hepatotoxicity. Monitoring liver function tests is recommended during prolonged use.

Introduction:

Varicella Zoster Virus (VZV) is a highly contagious virus belonging to the Herpesviridae family, responsible for causing two distinct diseases: varicella (chickenpox) as the primary infection and herpes zoster (shingles) upon reactivation. Chickenpox is characterized by a generalized, pruritic vesicular rash, primarily affecting children, while shingles typically presents as a localized, painful vesicular rash in older adults or immunocompromised individuals.

Etiology and Pathogenesis:

• Primary Infection (Varicella): The virus enters the body through the respiratory tract or conjunctiva and spreads via the bloodstream to the skin, where it causes the characteristic vesicular rash. After the primary infection, VZV remains dormant in the sensory nerve ganglia.

• Reactivation (Herpes Zoster): Reactivation of the latent virus occurs years later, usually due to immune suppression, aging, or stress. The virus travels along the sensory nerves to the skin, causing shingles, which manifests as a painful, localized rash in a dermatomal distribution.

Transmission:

• Mode of Transmission: Varicella is primarily spread through respiratory droplets or direct contact with vesicular fluid from the rash. It is highly contagious, with an incubation period of about 10-21 days.

• Contagious Period: Individuals with chickenpox are contagious 1-2 days before the rash appears and until all lesions have crusted over. For herpes zoster, the contagious period lasts until the lesions have crusted, but it primarily poses a risk to those who have not had chickenpox or are unvaccinated.

Clinical Features:

Varicella (Chickenpox):

• Rash: The hallmark of chickenpox is a pruritic, vesicular rash that starts on the face, scalp, and trunk before spreading to the extremities. The rash progresses through stages: macules, papules, vesicles, pustules, and crusts, often with lesions at different stages present simultaneously (described as "dew drops on a rose petal").

• Systemic Symptoms: Fever, malaise, headache, and loss of appetite often precede the rash.

• Complications: Bacterial superinfection of skin lesions, pneumonia, encephalitis, and Reye’s syndrome (especially if aspirin is used).

Herpes Zoster (Shingles):

• Rash: Painful, unilateral vesicular rash in a dermatomal distribution, commonly on the trunk but can occur on any part of the body. The rash typically does not cross the midline.

• Prodrome: Pain, itching, or tingling in the affected dermatome may precede the rash by several days.

• Complications: Postherpetic neuralgia (persistent pain in the affected area after the rash resolves), secondary bacterial infection, ocular involvement (herpes zoster ophthalmicus), and neurological complications such as meningitis or myelitis.

Differential Diagnosis:

• Varicella: Measles (characterized by Koplik spots and a maculopapular rash), Hand-Foot-Mouth disease (vesicles on hands, feet, and mouth), and insect bites.

• Herpes Zoster: Herpes simplex virus infections (localized vesicular rash but typically without dermatomal distribution), contact dermatitis, and impetigo.

Diagnosis:

• Clinical Diagnosis: Based on characteristic rash and history.

• Laboratory Testing: Can include direct fluorescent antibody (DFA) testing, PCR, or viral culture from lesion swabs. Serology can detect VZV-specific IgM (acute infection) or IgG (past infection or immunity).

Treatment:

Varicella:

• Supportive Care: Antihistamines for itching, acetaminophen for fever (avoid aspirin due to Reye’s syndrome risk), and maintaining good hydration.

• Antivirals: Acyclovir may be used in high-risk patients (e.g., immunocompromised, adolescents, adults) to reduce severity and complications.

• Prevention: Varicella vaccine (live attenuated) is highly effective in preventing chickenpox and is part of routine childhood immunization schedules.

Herpes Zoster:

• Antivirals: Acyclovir, valacyclovir, or famciclovir initiated within 72 hours of rash onset to reduce the severity and duration of symptoms and risk of complications like postherpetic neuralgia.

• Pain Management: Analgesics, topical lidocaine, and sometimes corticosteroids to manage acute pain.

• Vaccination: Zoster vaccine recommended for adults aged 50 and older to reduce the risk of shingles and postherpetic neuralgia.

Complications:

• Varicella: Severe complications are more common in adults, immunocompromised individuals, and pregnant women, including varicella pneumonia, encephalitis, and severe skin infections.

• Herpes Zoster: Postherpetic neuralgia is the most common complication, along with secondary infections and, in cases of ophthalmic involvement, potential vision loss.

Introduction:

Herpes Zoster, commonly known as shingles, is a viral infection caused by the reactivation of the Varicella Zoster Virus (VZV), the same virus responsible for chickenpox. After a primary infection with chickenpox, VZV remains dormant in the dorsal root ganglia of the sensory nerves. Reactivation of the virus, often due to a decline in immune function, leads to shingles, characterized by a painful, unilateral vesicular rash typically confined to a single dermatome. Shingles can occur at any age but is more common in older adults and immunocompromised individuals.

Etiology and Pathogenesis:

• Viral Reactivation: The exact mechanism of VZV reactivation is not fully understood, but it is believed to be triggered by immunosuppression, aging, stress, or other factors that weaken the immune system, allowing the dormant virus to reactivate and travel along the sensory nerves to the skin.

• Risk Factors: Age (particularly over 50 years), immunosuppression (due to conditions like HIV, cancer, or immunosuppressive therapies), psychological stress, and recent physical trauma are common risk factors.

Clinical Features:

• Prodrome: Before the onset of the rash, patients may experience prodromal symptoms such as localized pain, burning, itching, or tingling in the affected dermatome. This phase can last from 1 to 5 days.

• Rash: The characteristic rash of shingles begins as erythematous macules and papules that quickly evolve into clusters of clear vesicles. These vesicles eventually become pustular, rupture, and crust over within 7-10 days.

• Distribution: The rash is typically unilateral and follows the distribution of a single dermatome, commonly on the trunk but can occur on any part of the body, including the face. It usually does not cross the midline.

• Pain: Pain is a hallmark of shingles, often described as sharp, stabbing, or burning. It can be severe and debilitating, persisting even after the rash resolves.

Complications:

• Postherpetic Neuralgia (PHN): The most common complication, characterized by persistent pain in the affected dermatome lasting more than 90 days after the rash has healed. PHN can be severe and chronic, significantly affecting quality of life.

• Herpes Zoster Ophthalmicus: Involvement of the ophthalmic branch of the trigeminal nerve, which can lead to serious complications including keratitis, uveitis, and potential vision loss.

• Secondary Bacterial Infection: The vesicular lesions can become secondarily infected with bacteria, leading to cellulitis or impetigo.

• Neurological Complications: Meningitis, encephalitis, or myelitis can occur, though these are less common.

• Ramsay Hunt Syndrome: Occurs when VZV affects the facial nerve near the ear, leading to facial paralysis, ear pain, and vesicles in the ear canal or on the tongue.

Differential Diagnosis:

• Herpes Simplex Virus (HSV): Presents with recurrent vesicular lesions, often on the lips or genital area, but lacks the dermatomal distribution typical of shingles.

• Contact Dermatitis: Itchy, erythematous rash that lacks the vesicular nature and pain associated with shingles.

• Impetigo: Bacterial infection with honey-colored crusts but without the prodromal pain or dermatomal pattern of shingles.

Diagnosis:

• Clinical Diagnosis: Based on the characteristic dermatomal rash and history of pain preceding the rash.

• Laboratory Testing: PCR testing of vesicular fluid is the most sensitive method to confirm VZV infection. Direct fluorescent antibody (DFA) testing and viral culture can also be used but are less sensitive.

• Serology: Not typically used for diagnosis but can be helpful in specific situations.

Treatment:

• Antiviral Therapy: Early initiation of antiviral medications within 72 hours of rash onset is crucial to reduce the severity and duration of symptoms and to lower the risk of complications such as PHN.

  • Examples: Acyclovir, Valacyclovir, and Famciclovir are commonly prescribed.

• Pain Management: Analgesics, including NSAIDs, acetaminophen, and sometimes opioids, are used to manage acute pain. For severe cases, nerve blocks or gabapentinoids (e.g., gabapentin, pregabalin) may be necessary.

• Corticosteroids: May be used in combination with antiviral therapy to reduce inflammation and pain, though their use remains controversial.

• Topical Treatments: Lidocaine patches or capsaicin cream may be used for localized pain relief.

Prevention:

• Vaccination: The recombinant zoster vaccine (Shingrix) is recommended for adults aged 50 years and older, as well as immunocompromised individuals, to reduce the risk of shingles and its complications. The vaccine is more than 90% effective at preventing shingles and PHN.

• Avoidance of Triggers: Maintaining a healthy immune system through a balanced diet, regular exercise, and stress management can help reduce the risk of VZV reactivation.

Introduction:

Warts, or verrucae, are benign skin growths caused by infection with the human papillomavirus (HPV). They can appear on various parts of the body, including the hands, feet, face, and genital area. Warts are common and can affect people of all ages, although they are more prevalent in children and adolescents. While generally harmless, warts can be cosmetically displeasing, painful, and contagious.

Etiology and Pathogenesis:

• Causative Agent: Warts are caused by different types of HPV, a DNA virus that infects the epithelial cells of the skin and mucous membranes. There are over 100 HPV subtypes, each associated with specific types of warts.

• Transmission: HPV is transmitted through direct contact with infected skin or surfaces, including minor abrasions or cuts that facilitate viral entry. Warts can spread through autoinoculation (self-infection) or via contaminated objects like towels, razors, or floors in communal areas.

• Pathogenesis: After infection, HPV induces hyperplasia of the epithelium, leading to the formation of characteristic wart lesions. The virus remains confined to the epidermis, which explains why warts do not typically cause systemic symptoms.

Types of Warts:

• Common Warts (Verruca Vulgaris):

  • Appearance: Firm, raised lesions with a rough, cauliflower-like surface. Typically found on the fingers, hands, and knees.

  • Common HPV Types: HPV-2, HPV-4.

• Plantar Warts (Verruca Plantaris):

  • Appearance: Thick, painful lesions on the soles of the feet. They can be single or clustered (mosaic warts) and may have small black dots (thrombosed capillaries) within them.

  • Common HPV Types: HPV-1, HPV-2, HPV-4.

• Flat Warts (Verruca Plana):

  • Appearance: Small, smooth, flat-topped lesions often found on the face, neck, hands, and legs. These warts are less raised than common warts.

  • Common HPV Types: HPV-3, HPV-10.

• Filiform Warts:

  • Appearance: Long, narrow, finger-like projections commonly appearing on the face, around the eyes, lips, or nose.

  • Common HPV Types: HPV-1, HPV-2.

• Genital Warts (Condyloma Acuminata):

  • Appearance: Soft, flesh-colored lesions that appear on the genital and perianal areas. These can be small or form large, cauliflower-like masses.

  • Common HPV Types: HPV-6, HPV-11 (low-risk types), distinct from high-risk HPV types associated with cancer.

• Subungual and Periungual Warts:

  • Appearance: Rough, irregular lesions found around or under the fingernails and toenails, which can disrupt nail growth.

Differential Diagnosis:

• Seborrheic Keratosis: Benign, pigmented skin growths that may resemble warts but usually occur in older adults and have a "stuck-on" appearance.

• Calluses and Corns: Thickened areas of skin due to friction or pressure, usually on feet or hands, which lack the thrombosed capillaries seen in warts.

• Molluscum Contagiosum: Viral infection presenting with small, shiny, dome-shaped papules with a central dimple, often confused with warts in children.

• Squamous Cell Carcinoma: Can mimic warts, especially when presenting as keratotic lesions, but is typically more invasive and may bleed or ulcerate.

Diagnosis:

• Clinical Diagnosis: Warts are primarily diagnosed based on their characteristic appearance. Dermatoscopy can aid in visualization of typical features, such as thrombosed capillaries.

• Biopsy: Rarely needed, but may be performed if the diagnosis is uncertain or to exclude malignancy in atypical lesions.

Treatment:

• Topical Treatments:

  • Salicylic Acid: Over-the-counter treatment that exfoliates the affected skin. It should be applied daily after soaking the wart in warm water and debriding dead tissue.

  • Cryotherapy: Freezing the wart with liquid nitrogen is a common and effective treatment, requiring multiple sessions spaced a few weeks apart.

  • Cantharidin: A blistering agent applied in-office, causing the wart to lift off the skin as a blister forms underneath.

  • Imiquimod: An immune response modifier used for genital warts and resistant common warts.

• Chemical Peels:

  • Trichloroacetic Acid: Applied in-office to destroy wart tissue, particularly useful for genital warts.

• Surgical Treatments:

  • Curettage and Electrosurgery: Scraping off the wart followed by cauterization; typically used for larger or stubborn warts.

  • Laser Therapy: Pulsed dye lasers target the blood vessels feeding the wart, causing it to shrink and fall off.

• Immunotherapy:

  • Intralesional Injections: Injecting antigens like candida or mumps antigens to stimulate an immune response against the wart.

  • Topical 5-Fluorouracil: Used in cases resistant to standard therapies.

Prevention:

• Avoid Direct Contact: Minimize skin-to-skin contact with warts, and avoid sharing personal items such as towels or razors.

• Use Protective Footwear: Wearing sandals or flip-flops in communal showers and pool areas can reduce the risk of plantar warts.

• Vaccination: The HPV vaccine can prevent genital warts and certain cancers associated with high-risk HPV types.

Molluscum contagiosum is a common viral skin infection caused by the Molluscum contagiosum virus (MCV), a member of the Poxviridae family. The condition is characterized by small, flesh-colored, dome-shaped papules with a central dimple (umbilication). Molluscum contagiosum is primarily seen in children, sexually active adults, and immunocompromised individuals. It is generally benign and self-limiting but can persist for several months to years without treatment.

Etiology and Pathogenesis:

• Causative Agent: The infection is caused by the Molluscum contagiosum virus, which has four types (MCV-1 to MCV-4). MCV-1 is the most common and least severe, while MCV-2 is more often associated with sexually transmitted cases in adults.

• Transmission: The virus spreads through direct skin-to-skin contact, including sexual contact, or indirectly via contaminated objects such as towels, clothing, or gym equipment. It can also spread through autoinoculation by scratching or touching the lesions and then other body parts.

• Pathogenesis: The virus infects the epidermis, leading to the formation of characteristic lesions. It induces keratinocyte proliferation, resulting in the raised, pearly papules. The central umbilication is due to viral replication within the cells, which eventually rupture and release the virus.

Clinical Features:

• Lesions: Molluscum contagiosum presents as small (2-5 mm), smooth, shiny, flesh-colored or pearly papules with a characteristic central umbilication. The lesions are usually painless but can become itchy or inflamed, especially if irritated or scratched.

• Distribution: Lesions commonly appear on the face, trunk, extremities, and genitals. In adults, lesions often occur in the genital area, lower abdomen, and inner thighs due to sexual transmission. In immunocompromised individuals, such as those with HIV, lesions may be more extensive, larger, and resistant to treatment.

• Number and Progression: Lesions can range from a few to several hundred and may appear in clusters. They typically resolve spontaneously within 6-12 months but can persist longer, especially in immunocompromised patients.

Differential Diagnosis:

• Warts: Caused by HPV, warts have a rougher surface without central umbilication.

• Folliculitis: Presents with inflamed pustules associated with hair follicles, often lacking the characteristic umbilication of molluscum.

• Chickenpox: Varicella presents with widespread vesicular lesions in various stages, including blisters, unlike the uniform papules of molluscum.

• Basal Cell Carcinoma: Can present with pearly lesions but usually in older adults and lacks central umbilication.

Diagnosis:

• Clinical Diagnosis: Primarily based on the appearance of the characteristic lesions.

• Dermatoscopy: Can help visualize the central umbilication and enhance diagnostic accuracy.

• Histopathology: In uncertain cases, a biopsy can reveal characteristic intracytoplasmic inclusion bodies (Henderson-Patterson bodies) within keratinocytes.

• PCR Testing: Used in research or for complex cases, especially in immunocompromised patients.

Treatment:

• Observation: In healthy individuals, molluscum contagiosum often resolves spontaneously, so treatment is not always necessary unless for cosmetic reasons, to reduce spread, or due to complications like inflammation or secondary infection.

• Topical Therapies:

  • Cantharidin: A blistering agent applied by a healthcare provider to cause mild blistering and lesion resolution.

  • Podophyllotoxin: Used for genital lesions; it has antimitotic properties that disrupt viral replication.

  • Imiquimod: An immune response modifier applied topically to stimulate the body’s immune response against the virus.

  • Tretinoin: A topical retinoid used off-label to promote lesion clearance.

• Physical Removal:

  • Cryotherapy: Freezing the lesions with liquid nitrogen to destroy the infected cells.

  • Curettage: Scraping off the lesions with a sharp curette, typically done in a clinical setting under local anesthesia.

  • Laser Therapy: Pulsed dye laser or other laser treatments can target lesions effectively, especially in widespread or resistant cases.

• Systemic Treatment: Rarely needed but may include systemic antivirals in severely immunocompromised individuals.

Complications:

• Inflammation: Lesions can become red, swollen, and painful, often mistaken for secondary bacterial infection but typically a sign of an immune response.

• Secondary Infection: Scratching can lead to bacterial superinfection, commonly with Staphylococcus aureus.

• Eczema: Eczematous changes around the lesions are common, especially in children.

Prevention:

• Avoid Skin Contact: Minimize direct contact with lesions, and avoid sharing personal items like towels, clothing, or gym equipment.

• Hygiene: Regular hand washing and keeping affected areas clean and covered can help prevent spread.

• Avoid Scratching: Discourage scratching or picking at lesions to prevent autoinoculation and secondary infections.

Herpes Simplex Virus (HSV) is a common viral infection that affects the skin, mucous membranes, and sometimes the nervous system. It is caused by two types of viruses: HSV-1, which primarily causes oral herpes (cold sores), and HSV-2, which is usually responsible for genital herpes. Both HSV-1 and HSV-2 can cause lesions at other sites, depending on the mode of transmission. Herpes simplex infections are highly contagious and can recur throughout a person's life due to the virus's ability to remain latent in nerve ganglia.

Etiology and Pathogenesis:

• Causative Agents:

  • HSV-1: Primarily causes oral infections, such as cold sores, but can also cause genital infections.

  • HSV-2: Primarily causes genital herpes but can also cause oral lesions.

• Transmission: The virus spreads through direct contact with infected body fluids, including saliva, genital secretions, or contact with lesions. HSV can also be transmitted during asymptomatic shedding when no visible lesions are present.

• Pathogenesis: After initial infection, the virus travels along sensory nerves to the nerve ganglia, where it remains dormant. Reactivation of the virus, triggered by factors such as stress, illness, sun exposure, or immunosuppression, leads to recurrent outbreaks.

Clinical Features:

Oral Herpes (HSV-1):

• Primary Infection: Often asymptomatic but may present as gingivostomatitis in children, characterized by painful vesicles and ulcers in the mouth, fever, and lymphadenopathy.

• Recurrent Infection: Typically presents as cold sores or fever blisters on the lips or around the mouth. The lesions begin as small vesicles that rupture, forming painful ulcers that crust over and heal within 7-10 days.

Genital Herpes (HSV-2):

• Primary Infection: Symptoms can include multiple painful vesicles, ulcers on the genitalia, perineum, or anus, dysuria, fever, headache, and inguinal lymphadenopathy. Primary episodes are often more severe and longer-lasting than recurrent episodes.

• Recurrent Infection: Recurrent genital herpes presents with fewer lesions that are less painful and resolve more quickly, often preceded by a prodrome of tingling, itching, or pain.

Other Manifestations:

• Herpetic Whitlow: Painful infection of the fingers, common among healthcare workers and individuals who touch their mouth or genitals.

• Herpes Gladiatorum: Infection spread through skin-to-skin contact in contact sports like wrestling, leading to lesions on the face, neck, or arms.

• Herpes Keratitis: HSV infection of the cornea, which can lead to eye pain, redness, tearing, and potential vision loss if untreated.

• Neonatal Herpes: A severe, potentially life-threatening infection passed from mother to newborn during childbirth, leading to skin lesions, encephalitis, or disseminated infection.

• Herpes Encephalitis: A rare but serious complication primarily caused by HSV-1, characterized by fever, headache, confusion, seizures, and focal neurological deficits.

Differential Diagnosis:

• Aphthous Stomatitis: Mouth ulcers that resemble herpes but lack vesicular lesions and systemic symptoms.

• Hand-Foot-Mouth Disease: Caused by Coxsackievirus, presenting with vesicles on the hands, feet, and mouth, commonly in children.

• Syphilis: Can present with genital ulcers, but syphilitic lesions (chancres) are usually painless and heal without treatment.

• Impetigo: Bacterial infection causing pustules and honey-colored crusts, often around the mouth, but without the clear vesicular stage of herpes.

Diagnosis:

• Clinical Diagnosis: Based on characteristic lesions and patient history.

• Laboratory Testing:

  • PCR: Highly sensitive and specific, used to detect HSV DNA from lesion swabs or cerebrospinal fluid in cases of suspected encephalitis.

  • Viral Culture: Used less frequently due to lower sensitivity, particularly for recurrent lesions.

  • Direct Fluorescent Antibody (DFA) Testing: Can identify HSV in lesion samples.

  • Serology: Useful for determining past exposure to HSV-1 or HSV-2 but not for diagnosing active infections.

Treatment:

• Antiviral Medications: Acyclovir, Valacyclovir, and Famciclovir are the main antiviral drugs used to reduce the severity and duration of outbreaks. They are most effective when started at the onset of symptoms.

  • Episodic Treatment: Used during outbreaks to shorten duration and alleviate symptoms.

  • Suppressive Therapy: Daily antiviral medication to reduce the frequency of recurrences and decrease viral shedding, often used in individuals with frequent or severe outbreaks.

• Pain Management: Analgesics, topical anesthetics, and soothing ointments can help alleviate pain and discomfort associated with lesions.

• Preventive Measures: Avoiding direct contact with lesions, using condoms, and antiviral prophylaxis can reduce transmission risk.

Complications:

• Chronic Pain: Recurrent lesions can cause persistent pain or discomfort, particularly with genital herpes.

• Psychological Impact: Recurrent herpes infections can lead to significant emotional distress, anxiety, or depression due to stigma and fear of transmission.

• Disseminated Infection: Rare in healthy individuals but can occur in immunocompromised patients, leading to widespread skin involvement and systemic symptoms.

• Herpes Encephalitis: A potentially fatal complication requiring prompt antiviral treatment and supportive care.

Prevention:

• Safe Sexual Practices: Using condoms and avoiding sexual contact during outbreaks can reduce the risk of genital herpes transmission.

• Avoiding Direct Contact: Refrain from sharing items like lip balm, utensils, or razors that could spread the virus.

• Antiviral Prophylaxis: For those with frequent recurrences, daily antiviral medication can help prevent outbreaks and reduce the risk of transmission.

The Tzanck smear, also known as a Tzanck test or Tzanck preparation, is a rapid and simple diagnostic procedure used in dermatology to identify viral infections, particularly those caused by herpesviruses. This test involves scraping the base of a vesicle or blister to collect cells, which are then stained and examined under a microscope for characteristic cytological changes. The Tzanck smear is especially useful in diagnosing conditions like herpes simplex, varicella (chickenpox), herpes zoster (shingles), and other blistering skin disorders.

Indications:

• Herpes Simplex Virus (HSV): To confirm a diagnosis in patients presenting with vesicular lesions on the skin or mucous membranes.

• Varicella-Zoster Virus (VZV): To diagnose varicella (chickenpox) or herpes zoster (shingles) in patients with a vesicular or pustular rash.

• Pemphigus Vulgaris: To detect acantholytic cells, which are characteristic of this autoimmune blistering disorder.

• Other Bullous Disorders: Occasionally used to evaluate other blistering diseases, although its sensitivity and specificity are lower compared to viral infections.

Procedure:

1. Preparation: Clean the lesion site with alcohol or an antiseptic. The test is usually performed on fresh vesicles, bullae, or pustules for optimal results.

2. Specimen Collection: A sterile scalpel blade or a fine curette is used to unroof the vesicle or blister. The base of the lesion is gently scraped to collect cells.

3. Smear Preparation: The collected material is spread thinly on a glass slide.

4. Staining: The slide is air-dried and stained with a Giemsa, Wright, or methylene blue stain, which highlights cellular features.

5. Microscopic Examination: The stained smear is examined under a light microscope for diagnostic features.

Interpretation:

• Multinucleated Giant Cells: The presence of multinucleated giant cells with characteristic nuclear molding is a hallmark of herpesvirus infections (both HSV and VZV).

• Acantholytic Cells: In pemphigus vulgaris, the smear reveals acantholytic keratinocytes, which appear as rounded, detached cells with a large nucleus and prominent nucleoli.

• Cowdry Type A Inclusions: These are eosinophilic intranuclear inclusions that may be seen in herpesvirus-infected cells, though they are not always present.

• Ballooning Degeneration: Cells may show ballooning degeneration with enlarged, vacuolated cytoplasm, commonly seen in viral infections.

Advantages:

• Rapid Results: Provides quick, preliminary results that can aid in clinical decision-making.

• Cost-Effective: A low-cost diagnostic tool compared to other more sophisticated techniques.

• Ease of Use: Simple to perform and requires minimal equipment and expertise.

Limitations:

• Low Specificity: While the Tzanck smear is useful for detecting viral cytopathic effects, it cannot distinguish between HSV-1, HSV-2, and VZV. Further confirmatory tests (e.g., PCR, viral culture) are often needed.

• False Negatives: The sensitivity of the Tzanck smear is lower compared to other diagnostic methods, and negative results do not rule out infection.

• Operator Dependent: Accurate interpretation requires experience and familiarity with cytological features, and results may vary depending on the quality of specimen collection and preparation.

Differential Diagnosis:

• The Tzanck smear can detect cytological changes suggestive of viral infections, but it does not differentiate between different types of herpesviruses. Other conditions that may be considered include pemphigus vulgaris and other vesiculobullous diseases.

Confirmatory Tests:

• Polymerase Chain Reaction (PCR): Highly sensitive and specific for detecting viral DNA and differentiating between HSV-1, HSV-2, and VZV.

• Direct Fluorescent Antibody (DFA) Test: Can identify specific viral antigens on the smear.

• Viral Culture: Used less frequently due to time constraints but can provide definitive identification of the virus.

Leprosy, or Hansen’s disease, is a chronic infectious disease caused by Mycobacterium leprae, a slow-growing bacterium that primarily affects the skin, peripheral nerves, mucosa of the upper respiratory tract, and eyes. The disease presents with a broad spectrum of clinical manifestations and can lead to severe disabilities if not diagnosed and treated early. Leprosy is curable with multidrug therapy (MDT), and early detection is crucial to preventing complications and transmission.

Classification of Leprosy

1. Ridley-Jopling Classification:
Based on clinical, immunological, and histopathological findings, this system classifies leprosy into five types:

• Tuberculoid Leprosy (TT):

  • Few well-defined, hypopigmented, anesthetic skin lesions with significant nerve involvement.

  • Strong cell-mediated immunity; paucibacillary with few or no bacilli.

• Borderline Tuberculoid (BT):

  • More numerous lesions than TT, with less sharp borders and moderate nerve involvement.

  • Moderate cell-mediated immunity; intermediate between TT and BB.

• Mid-Borderline (BB):

  • Unstable form with a mix of features from both tuberculoid and lepromatous poles.

  • Intermediate immune response; lesions are numerous and less defined.

• Borderline Lepromatous (BL):

  • Numerous, poorly defined skin lesions with variable nerve involvement.

  • Weak cell-mediated immunity; multibacillary with more abundant bacilli.

• Lepromatous Leprosy (LL):

  • Numerous, symmetrical lesions including nodules, plaques, and thickened dermis with extensive nerve involvement.

  • Poor cell-mediated immunity; multibacillary with high bacillary load.

2. World Health Organization (WHO) Classification:
A simpler classification based on skin lesions and bacterial load:

• Paucibacillary (PB) Leprosy:

  • 1-5 skin lesions without detectable bacilli in skin smears.

• Multibacillary (MB) Leprosy:

  • More than 5 skin lesions or positive skin smears with detectable bacilli.

Microbiology

• Causative Agent: Mycobacterium leprae is an acid-fast, obligate intracellular bacillus that prefers cooler areas of the body such as the skin, peripheral nerves, and nasal mucosa. It cannot be cultured in vitro and has a long incubation period, typically ranging from 6 months to several years.

• Transmission: Mainly spread through respiratory droplets from untreated patients, though direct contact with the skin lesions is also a possible route. Prolonged close contact increases the risk of transmission.

• Host Response: The clinical manifestations reflect the host’s immune response, with strong cell-mediated immunity confining the infection to a few lesions (tuberculoid forms), while weak immunity allows widespread dissemination (lepromatous forms).

Pathogenesis

• Immune Response: The immune response determines the type of leprosy. A robust Th1 response, involving activated macrophages, controls the infection in tuberculoid forms. In contrast, a Th2 response with poor macrophage activation leads to lepromatous leprosy with widespread bacillary growth.

• Nerve Involvement: M. leprae targets Schwann cells in peripheral nerves, causing nerve inflammation, thickening, and damage, leading to sensory loss and, in severe cases, motor dysfunction and deformities.

• Skin Lesions: The lesions arise from the direct infection of skin cells and the host’s immune response, ranging from isolated, well-demarcated patches in tuberculoid forms to widespread, poorly defined lesions in lepromatous forms.

Clinical Features

• Skin Lesions: Present as hypopigmented or erythematous patches, plaques, nodules, or diffuse infiltration. Lesions are typically anesthetic due to nerve involvement.

• Nerve Involvement: Commonly presents with thickened peripheral nerves, sensory loss (especially temperature sensation), muscle weakness, and deformities.

• Other Features: Includes madarosis (loss of eyebrows), nasal collapse, and eye involvement leading to blindness in severe cases.

Diagnosis

• Clinical Evaluation: Diagnosis is based on skin lesions with loss of sensation, nerve enlargement, and other characteristic clinical features.

• Laboratory Tests:

  • Skin Smear: A sample stained with Ziehl-Neelsen stain to detect acid-fast bacilli, primarily in multibacillary cases.

  • Skin Biopsy: Histopathology can confirm the diagnosis and classify the disease, showing granulomas in tuberculoid forms and numerous bacilli in lepromatous forms.

  • Lepromin Test: Not diagnostic but helps assess immune response; positive in tuberculoid and negative in lepromatous leprosy.

Lepra Reactions

Lepra reactions are acute inflammatory complications that occur in leprosy and can lead to further nerve damage and disability. There are two main types:

• Type 1 Reaction (Reversal Reaction):

  • Occurs due to an increase in cell-mediated immunity, leading to inflammation of existing lesions and nerves.

  • Clinically presents with redness, swelling, and pain in existing lesions, and possible new nerve involvement.

  • Management: Treated with corticosteroids to reduce inflammation and prevent nerve damage.

• Type 2 Reaction (Erythema Nodosum Leprosum - ENL):

  • Due to immune complex deposition, commonly seen in lepromatous leprosy.

  • Presents with painful nodules, systemic symptoms like fever, malaise, and possible organ involvement (e.g., arthritis, iritis, orchitis).

  • Management: Treated with corticosteroids, thalidomide (not in pregnancy), or clofazimine.

Treatment

Multidrug Therapy (MDT):
MDT is the cornerstone of leprosy treatment, effectively curing the disease and preventing drug resistance.

• Paucibacillary (PB) Leprosy:

  • Duration: 6 months.

  • Medications:

    • Rifampicin: 600 mg once a month (supervised).

    • Dapsone: 100 mg daily (self-administered).

• Multibacillary (MB) Leprosy:

  • Duration: 12 months.

  • Medications:

    • Rifampicin: 600 mg once a month (supervised).

    • Dapsone: 100 mg daily (self-administered).

    • Clofazimine: 300 mg once a month (supervised) and 50 mg daily (self-administered).

Management of Reactions:

• Corticosteroids: Used to manage nerve inflammation in reversal reactions and systemic symptoms in ENL.

• Thalidomide: Effective in treating ENL, especially in cases unresponsive to steroids, but is contraindicated in pregnancy due to teratogenicity.

• Clofazimine: An anti-inflammatory used in chronic or severe ENL.

Prevention and Control:

• Early Detection and Treatment: Reduces transmission and prevents complications.

• Contact Screening: Monitoring and providing prophylaxis for close contacts of leprosy patients.

• BCG Vaccine: Provides partial protection against leprosy and is part of routine immunization in endemic areas.

Eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition characterized by itchy, red, and inflamed patches on the skin. It commonly affects children but can persist into adulthood or start later in life. Eczema is often associated with other atopic conditions, such as asthma and allergic rhinitis, and has a significant impact on the quality of life due to its chronic nature and intense pruritus.

Etiology:

• Genetic Factors: A strong family history of atopic diseases (eczema, asthma, allergic rhinitis) suggests a genetic predisposition. Mutations in the filaggrin gene, which is crucial for skin barrier function, are strongly associated with eczema.

• Immune Dysregulation: Eczema is associated with a Th2-dominated immune response, leading to increased levels of IgE and heightened sensitivity to environmental allergens.

• Environmental Triggers: Common triggers include allergens (dust mites, pollen, pet dander), irritants (soaps, detergents, perfumes), temperature extremes, and stress.

• Skin Barrier Dysfunction: Impaired barrier function allows allergens, irritants, and microbes to penetrate the skin more easily, leading to inflammation and increased susceptibility to infections.

Pathogenesis:

• Skin Barrier Dysfunction: Defects in the skin barrier, such as reduced levels of ceramides and filaggrin, lead to increased transepidermal water loss and vulnerability to environmental irritants and allergens.

• Immune Response: A skewed immune response involving T-helper cells (predominantly Th2) leads to chronic inflammation, characterized by the release of cytokines such as IL-4, IL-13, and IL-31, which contribute to itching and inflammation.

• Microbial Colonization: The skin of eczema patients is frequently colonized by Staphylococcus aureus, which can exacerbate inflammation and increase the risk of secondary infections.

Clinical Features

• Itching (Pruritus): The hallmark symptom of eczema, often severe, leading to scratching that worsens the skin barrier dysfunction and inflammation.

• Acute Lesions: Characterized by red, inflamed, edematous skin with vesicles, oozing, and crusting. These lesions are most common in flares and can be intensely itchy.

• Chronic Lesions: Prolonged scratching and rubbing lead to lichenification (thickening of the skin), excoriations, and hyperpigmentation or hypopigmentation.

• Distribution:

  • Infants: Commonly affects the face (cheeks), scalp, and extensor surfaces of the limbs.

  • Children and Adults: Predominantly involves flexural areas (e.g., elbows, knees, wrists, ankles), neck, and hands.

• Associated Features: Dry skin (xerosis), allergic shiners (dark circles under the eyes), Dennie-Morgan lines (infraorbital folds), and increased palmar hyperlinearity.

Diagnosis

• Clinical Diagnosis: Primarily based on history and physical examination. Key diagnostic criteria include pruritus, typical morphology and distribution of lesions, chronic or relapsing course, and a personal or family history of atopy.

• Additional Testing:

  • Allergy Testing: Skin prick tests or specific IgE testing may identify triggers but are not required for diagnosis.

  • Patch Testing: May be performed to rule out allergic contact dermatitis if contact allergens are suspected.

• Severity Assessment: Tools like the Eczema Area and Severity Index (EASI) or Scoring Atopic Dermatitis (SCORAD) are used to assess disease severity and monitor treatment response.

Management and Treatment

1. Skincare and Barrier Repair:

• Moisturizers: Frequent application of emollients to restore the skin barrier, reduce dryness, and prevent flare-ups. Products containing ceramides, urea, or glycerin are particularly effective.

• Avoid Triggers: Identifying and avoiding known triggers, including irritants, allergens, and extremes in temperature or humidity.

2. Pharmacological Treatment:

• Topical Corticosteroids: The mainstay of treatment for controlling inflammation during flares. Potency is chosen based on the severity and location of lesions.

• Topical Calcineurin Inhibitors: Tacrolimus and pimecrolimus are used for sensitive areas (e.g., face, neck) or as steroid-sparing agents for long-term management.

• Topical PDE-4 Inhibitors: Crisaborole is a newer non-steroidal option for mild to moderate eczema, reducing inflammation and itching.

• Oral Antihistamines: Used primarily for pruritus management, though their efficacy in eczema is variable.

• Systemic Treatments:

  • Oral Corticosteroids: Used short-term for severe flares but avoided long-term due to side effects.

  • Immunosuppressants: Cyclosporine, methotrexate, azathioprine, or mycophenolate mofetil may be used for severe, refractory cases.

  • Biologics: Dupilumab, a monoclonal antibody targeting IL-4 and IL-13, is approved for moderate to severe eczema that is inadequately controlled with topical treatments.

3. Managing Infections:

• Antibiotics: Oral or topical antibiotics may be used to treat secondary bacterial infections, commonly caused by Staphylococcus aureus.

• Antiviral Treatments: For eczema herpeticum (HSV infection), systemic antiviral therapy (e.g., acyclovir) is required.

4. Phototherapy:

• Narrowband UVB: Used for moderate to severe eczema unresponsive to topical treatments. It helps reduce inflammation and pruritus.

Complications

• Secondary Infections: Increased susceptibility to bacterial (e.g., impetigo) and viral (e.g., eczema herpeticum) infections.

• Eczema Herpeticum: A serious complication caused by herpes simplex virus infection, presenting with widespread vesicular lesions and systemic symptoms.

• Impact on Quality of Life: Chronic itching, sleep disturbances, and visible skin lesions can lead to significant psychological distress, including anxiety and depression.

Exfoliative dermatitis, also known as erythroderma, is a severe and potentially life-threatening condition characterized by widespread erythema, scaling, and peeling of the skin covering more than 90% of the body surface area. It can result from a variety of underlying skin disorders, systemic diseases, drug reactions, or be idiopathic. The condition disrupts the normal barrier function of the skin, leading to complications such as fluid loss, electrolyte imbalances, and increased susceptibility to infections.

Etiology

Exfoliative dermatitis can be caused by several conditions, including:

1. Pre-existing Skin Disorders:

• Psoriasis: One of the most common causes; may progress to erythrodermic psoriasis.

• Atopic Dermatitis: Severe cases can evolve into erythroderma.

• Contact Dermatitis: Both irritant and allergic contact dermatitis can become generalized.

• Seborrheic Dermatitis: Can rarely lead to widespread exfoliation.

2. Drug Reactions:

• Medications: Common drugs implicated include antibiotics (e.g., penicillin, sulfonamides), anticonvulsants (e.g., phenytoin, carbamazepine), allopurinol, and gold salts.

• Drug Hypersensitivity Syndrome: Also known as DRESS syndrome, can present with erythroderma among other systemic symptoms.

3. Malignancies:

• Cutaneous T-cell Lymphoma (CTCL): Particularly Sézary syndrome, which is characterized by erythroderma, lymphadenopathy, and circulating malignant T-cells.

• Solid Tumors: Occasionally, internal malignancies can manifest with exfoliative dermatitis as a paraneoplastic syndrome.

4. Idiopathic:

• Unknown Causes: In some cases, the underlying cause cannot be identified despite thorough evaluation.

Pathogenesis

Exfoliative dermatitis results from extensive skin inflammation that disrupts the normal epidermal turnover and barrier function. This leads to:

• Increased Epidermal Turnover: Rapid shedding of the skin layers, leading to scaling and peeling.

• Loss of Barrier Function: Increased transepidermal water loss results in dehydration, fluid imbalance, and increased risk of infections.

• Systemic Effects: The extensive inflammatory response can affect thermoregulation, leading to hypothermia or hyperthermia, and contribute to systemic inflammation affecting the liver, kidneys, and cardiovascular system.

Clinical Features

• Widespread Erythema: Intense redness of the skin covering most of the body surface area.

• Scaling and Peeling: Fine or large flakes of skin that continuously shed, leading to an exfoliative appearance.

• Pruritus and Pain: Intense itching, burning, or pain are common and can be debilitating.

• Edema: Swelling of the skin, especially in the extremities, face, and eyelids, is frequently observed.

• Systemic Symptoms: Fever, malaise, chills, and weight loss are often present due to the extensive inflammation.

• Hair and Nail Changes: Hair loss (telogen effluvium) and nail dystrophy, including onycholysis (nail detachment) and shedding, are common.

Diagnosis

Clinical Diagnosis:
Diagnosis is primarily clinical, based on characteristic signs and symptoms.

Laboratory Tests:

• Complete Blood Count (CBC): May reveal anemia, leukocytosis, or eosinophilia.

• Biochemistry Panel: Monitors renal and hepatic function, electrolytes, and protein levels.

• Serum Albumin: Low levels are common due to protein loss through the skin.

• Skin Biopsy: Helps confirm the diagnosis and may suggest an underlying cause (e.g., psoriasis, cutaneous lymphoma).

• Patch Testing: Considered if allergic contact dermatitis is suspected as the cause.

Additional Evaluations:

• Drug History: A thorough review of medications to identify potential drug-induced exfoliative dermatitis.

• Screening for Malignancies: If no other cause is identified, especially in older patients, consider screening for internal malignancies.

Management and Treatment

1. Hospitalization:
Most patients require hospitalization, especially if they are experiencing systemic symptoms, fluid loss, or complications.

2. Supportive Care:

• Fluid and Electrolyte Management: Intravenous fluids and electrolytes are often necessary to manage dehydration and prevent renal failure.

• Temperature Regulation: Measures to maintain normal body temperature, including warm environments and heated blankets if hypothermic.

• Nutritional Support: High-protein diet or supplements to compensate for protein loss through the skin.

3. Skin Care:

• Emollients: Liberal use of emollients to moisturize the skin, reduce scaling, and support barrier repair.

• Wet Dressings: To soothe inflamed skin, reduce itching, and promote healing.

4. Pharmacological Treatment:

• Topical Steroids: Potent topical corticosteroids to reduce inflammation and control symptoms.

• Systemic Corticosteroids: Oral or intravenous steroids may be required in severe cases or those with systemic symptoms.

• Immunosuppressive Agents: Cyclosporine, methotrexate, or azathioprine may be used in refractory cases, particularly those related to autoimmune or inflammatory causes.

• Antibiotics: For secondary bacterial infections due to impaired skin barrier.

5. Treatment of Underlying Cause:

• Discontinuation of Offending Drugs: Immediate cessation of suspected causative medications.

• Treatment of Primary Skin Disease: Addressing the underlying cause, such as treating psoriasis with systemic agents or managing contact dermatitis with avoidance strategies.

• Management of Malignancies: Appropriate oncological treatment if an associated malignancy is identified.

Complications

• Infections: Due to compromised skin barrier, there is a high risk of secondary bacterial and fungal infections, including sepsis.

• Fluid and Electrolyte Imbalances: Significant fluid loss through the skin can lead to dehydration, hypovolemia, and renal impairment.

• Cardiovascular Strain: Increased cardiac workload due to thermoregulatory demands and systemic inflammation.

• Nutritional Deficiencies: Due to increased metabolic demands and protein loss, which can lead to cachexia.

Erythroderma, also known as generalized exfoliative dermatitis, is a severe and potentially life-threatening condition characterized by widespread erythema and scaling involving more than 90% of the body surface area. This condition can arise as a result of various underlying skin disorders, drug reactions, systemic diseases, or it can be idiopathic. Erythroderma disrupts normal skin function, leading to significant complications such as fluid loss, temperature dysregulation, and increased risk of infections.

Etiology

Erythroderma can result from a variety of causes, which include:

1. Pre-existing Skin Conditions:

• Psoriasis: Erythrodermic psoriasis is one of the common causes and can be triggered by abrupt discontinuation of systemic treatments or excessive use of topical corticosteroids.

• Atopic Dermatitis: Severe, uncontrolled eczema can evolve into erythroderma.

• Seborrheic Dermatitis: Rarely progresses to erythroderma.

• Contact Dermatitis: Both irritant and allergic types can generalize and cause erythroderma.

• Pityriasis Rubra Pilaris: A rare skin disorder that can lead to erythroderma with characteristic orange-red plaques.

2. Drug Reactions:

• Medications: Commonly implicated drugs include antibiotics (e.g., sulfonamides, penicillin), anticonvulsants (e.g., phenytoin, carbamazepine), allopurinol, and gold salts.

• Drug Hypersensitivity Syndromes: Includes conditions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

3. Malignancies:

• Cutaneous T-cell Lymphoma (CTCL): Particularly Sézary syndrome, a leukemic variant of CTCL, is strongly associated with erythroderma.

• Paraneoplastic Syndromes: Erythroderma may occasionally be associated with internal malignancies as part of a paraneoplastic syndrome.

4. Idiopathic:

• In some cases, no underlying cause can be identified despite thorough investigation.

Pathogenesis

The pathogenesis of erythroderma involves extensive inflammation of the skin, leading to:

• Increased Epidermal Turnover: Results in rapid shedding of the skin's outer layer, contributing to widespread scaling and peeling.

• Loss of Barrier Function: Compromised skin integrity leads to significant fluid loss, increased susceptibility to infections, and impaired temperature regulation.

• Systemic Inflammation: The extensive inflammatory process can lead to systemic symptoms, affecting multiple organ systems, including cardiovascular, renal, and hepatic functions.

Clinical Features

• Widespread Erythema: Intense redness of the skin that covers most of the body, often accompanied by scaling and peeling.

• Scaling: Fine to thick scaling is typically present, with constant shedding of skin.

• Pruritus: Severe itching is common and can be debilitating.

• Edema: Swelling of the skin, particularly on the extremities, face, and eyelids.

• Systemic Symptoms: Includes fever, malaise, chills, and weight loss, reflecting the systemic impact of extensive skin inflammation.

• Hair and Nail Changes: Hair loss (alopecia), including scalp and body hair, is common, along with nail changes such as onycholysis or nail shedding.

Diagnosis

Clinical Diagnosis:
Diagnosis is mainly clinical, based on the characteristic presentation of widespread erythema and scaling.

Laboratory Tests:

• Complete Blood Count (CBC): May show anemia, leukocytosis, eosinophilia, or lymphopenia, depending on the underlying cause.

• Biochemistry Panel: Monitors liver and renal function, electrolytes, and protein levels.

• Serum Albumin: Often decreased due to protein loss through the skin.

• Skin Biopsy: Helps to confirm the diagnosis and may suggest the underlying cause, such as psoriasis, CTCL, or drug reaction.

• Patch Testing: Can be helpful if allergic contact dermatitis is suspected.

Additional Evaluations:

• Drug History: Review of medications to identify potential drug-induced erythroderma.

• Screening for Malignancies: Includes imaging and laboratory tests to rule out internal malignancies or cutaneous lymphoma.

Management and Treatment

1. Hospitalization:
Hospitalization is often required for close monitoring, supportive care, and to manage complications.

2. Supportive Care:

• Fluid and Electrolyte Management: Intravenous fluids and electrolytes may be needed to manage dehydration and prevent renal failure.

• Temperature Regulation: Measures such as maintaining a warm environment and using heated blankets help prevent hypothermia due to loss of the skin's insulating function.

• Nutritional Support: High-protein diets and nutritional supplementation are necessary due to increased metabolic demands and protein loss.

3. Skin Care:

• Emollients: Frequent application of emollients to restore the skin barrier, reduce scaling, and soothe irritation.

• Wet Wraps: Can be used to moisturize the skin and provide relief from itching and discomfort.

4. Pharmacological Treatment:

• Topical Corticosteroids: To reduce inflammation and manage symptoms, particularly during flares.

• Systemic Corticosteroids: Oral or intravenous corticosteroids may be required in severe cases, especially if associated with systemic symptoms.

• Immunosuppressive Agents: Options include cyclosporine, methotrexate, or azathioprine, particularly in cases linked to autoimmune or inflammatory conditions.

• Biologic Agents: Biologics, such as monoclonal antibodies targeting specific immune pathways, may be used for conditions like psoriasis-associated erythroderma.

• Antibiotics: For treating secondary bacterial infections that are common due to impaired skin barrier.

5. Treat Underlying Cause:

• Discontinuation of Offending Medications: Stop any suspected drugs that may be causing erythroderma.

• Management of Primary Skin Diseases: Appropriate treatment of underlying conditions such as psoriasis, atopic dermatitis, or seborrheic dermatitis.

• Oncological Treatment: Referral to oncology for appropriate management if associated with malignancy, such as CTCL.

Complications

• Infections: The disrupted skin barrier increases the risk of secondary bacterial and fungal infections, including sepsis.

• Fluid and Electrolyte Imbalances: Significant fluid loss can lead to dehydration, hypovolemia, and renal dysfunction.

• Cardiovascular Strain: The increased metabolic demand and systemic inflammation can put a strain on the cardiovascular system.

• Nutritional Deficiencies: Due to increased metabolic needs and protein loss, leading to potential weight loss and cachexia.

Fixed Drug Eruptions (FDE)

Introduction:

Fixed Drug Eruptions (FDE) are a type of adverse drug reaction characterized by the appearance of well-defined, round or oval, erythematous or violaceous patches that recur at the same site upon re-exposure to the offending drug. These lesions often develop within hours to days of drug exposure and can involve any area of the body, including mucosal surfaces. FDEs are usually benign but can cause significant discomfort and hyperpigmentation.

Etiology:

• Common Offending Drugs:

  • Antibiotics: Sulfonamides, tetracyclines, and penicillins.

  • NSAIDs: Ibuprofen, naproxen, and aspirin.

  • Antifungals: Fluconazole.

  • Others: Barbiturates, carbamazepine, and phenolphthalein (formerly used in laxatives).

Pathogenesis:

• FDEs result from a delayed-type hypersensitivity reaction mediated by cytotoxic T-cells. Upon initial exposure, these cells are activated and migrate to the skin or mucosa. Upon re-exposure to the drug, these sensitized T-cells release inflammatory mediators, leading to localized tissue damage and lesion formation.

Clinical Features:

• Lesions: Erythematous to violaceous macules that may evolve into edematous plaques or blisters. Lesions are typically solitary but can be multiple.

• Recurrence: Lesions recur at the same site(s) upon re-exposure to the offending drug.

• Mucosal Involvement: Commonly affects the lips, genitals, and perianal area.

• Post-inflammatory Hyperpigmentation: Residual dark pigmentation is often left after the acute lesions resolve.

Diagnosis:

• Clinical History: Correlation of drug intake with lesion appearance and recurrence at the same site.

• Skin Biopsy: Shows vacuolar interface dermatitis with necrotic keratinocytes; useful if diagnosis is unclear.

• Patch Testing: Can help identify the causative drug but has variable sensitivity and specificity in FDE.

Treatment:

• Discontinuation of Offending Drug: The primary treatment is to stop the responsible medication.

• Symptomatic Management: Includes topical corticosteroids to reduce inflammation and antihistamines for itching.

• Rechallenge: Sometimes performed under medical supervision to confirm the offending drug, especially if discontinuation is not feasible.

Prevention:

• Avoid Re-exposure: Patients should avoid the causative drug and be educated about potential cross-reactivity with similar drugs.

• Medical Alert Identification: Patients may benefit from wearing medical alert bracelets or carrying cards that identify their drug allergies.

Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)

Introduction:
Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are severe, life-threatening mucocutaneous reactions characterized by extensive epidermal detachment, mucous membrane involvement, and systemic symptoms. SJS and TEN are part of a spectrum distinguished mainly by the extent of skin detachment: SJS involves less than 10% of the body surface area (BSA), SJS/TEN overlap involves 10-30% BSA, and TEN involves more than 30% BSA. These conditions are medical emergencies that require immediate hospitalization, often in an intensive care unit or burn unit.

Etiology:

• Common Offending Drugs:

  • Antibiotics: Sulfonamides, penicillins, and cephalosporins.

  • Antiepileptics: Phenytoin, carbamazepine, lamotrigine.

  • NSAIDs: Especially oxicam derivatives.

  • Allopurinol: Commonly implicated in SJS/TEN.

• Infections: Mycoplasma pneumoniae and viral infections (e.g., herpes simplex) can also trigger SJS.

Pathogenesis:

• SJS/TEN result from a severe hypersensitivity reaction, often drug-induced, where cytotoxic T-cells and natural killer (NK) cells induce massive keratinocyte apoptosis. This leads to widespread epidermal necrosis and detachment.

Clinical Features:

• Prodrome: Patients often experience a prodrome of fever, malaise, sore throat, and conjunctivitis 1-3 days before the onset of skin lesions.

• Skin Lesions: Initial lesions are erythematous macules or flat atypical target lesions that quickly progress to blistering and epidermal detachment.

• Mucosal Involvement: Painful erosions can affect the oral, ocular, and genital mucosa, leading to severe complications like blindness, dysphagia, and urogenital scarring.

• Systemic Involvement: Can include respiratory distress, gastrointestinal involvement, and acute kidney injury.

Diagnosis:

• Clinical Diagnosis: Based on the appearance of skin lesions, extent of skin detachment, and history of recent drug exposure.

• Skin Biopsy: Shows full-thickness epidermal necrosis with minimal inflammatory infiltrate, which is diagnostic of SJS/TEN.

• SCORTEN Score: A severity-of-illness scale that helps predict mortality and guide management, based on factors like age, heart rate, and extent of skin detachment.

Treatment:

• Immediate Discontinuation of Offending Drug: The first and most crucial step in management.

• Supportive Care: Includes fluid and electrolyte management, temperature regulation, and pain control. Care is best provided in a specialized unit with experience in severe skin conditions, such as a burn unit.

• Wound Care: Involves managing skin lesions as partial-thickness burns, using non-adherent dressings and sterile techniques to prevent infection.

• Infection Control: Prophylactic antibiotics are not recommended; however, close monitoring for sepsis is essential.

• Systemic Treatments:

  • Corticosteroids: Use is controversial but may be considered in the early stages.

  • Intravenous Immunoglobulin (IVIG): High-dose IVIG is thought to block Fas-mediated keratinocyte apoptosis, with some evidence supporting its use.

  • Cyclosporine: An immunosuppressant that has shown benefit in some studies for SJS/TEN by inhibiting T-cell activation.

  • Biologic Agents: Recent studies have explored the use of TNF-alpha inhibitors like etanercept, with promising results.

Complications:

• Ocular Complications: Severe conjunctivitis, corneal ulceration, and blindness.

• Respiratory Complications: Pneumonia, acute respiratory distress syndrome (ARDS).

• Long-term Sequelae: Chronic pain, scarring, nail loss, and psychological impact.

• Mortality: Higher in TEN, with mortality rates up to 30-50% depending on the extent of skin involvement and comorbidities.

Prevention:

• Genetic Screening: Certain genetic predispositions (e.g., HLA-B*1502 in Southeast Asians for carbamazepine) can guide drug selection and prevent SJS/TEN.

• Patient Education: Patients with a history of SJS/TEN should be thoroughly counseled to avoid the offending drug and drugs of similar class.